- Joint lab provides end-to-end solutions from bioprocessdevelopment to manufacturing for pre-clinical, clinical andcommercial supply
- Accelerates product availability for clinical trials with greaterreliability, cost effectiveness
- Offers seamless, robust transfer of optimized processes from small-scale R&D lab to large-scale commercial manufacturing
Billerica, Massachusetts, May 12, 2017 – MilliporeSigma today announced the opening of a new joint Process Scale-Up Lab in Bengaluru, India to provide end-to-end solutions from process development to scale-up manufacturing for pre-clinical, clinical and commercial supply.
“Both MilliporeSigma and Stelis bring technological expertise and an extensive bioprocess development and manufacturing portfolio that will help customers accelerate development of biopharmaceuticals for clinical trials and manufacturing with greater reliability and cost effectiveness,” said Udit Batra, CEO, MilliporeSigma.
The collaboration reinforces MilliporeSigma’s position as the premier supplier of process development and clinical state manufacturing solutions, materials and services needed for biologics production.
“In the biopharma space, where the process is the product, the Process Scale-Up Lab fulfils a critical need by offering clients a reliable process bridge between R&D and commercial scales,” said Joe Thomas, CEO of Stelis Biopharma. “The collaboration with MilliporeSigma completes the value proposition for CDMO customers by providing an end-to-end solution from process development and scale-up through to manufacturing for pre-clinical, clinical and commercial supply.”
The lab, located at the Stelis Biopharma R&D Facility in Bengaluru, was built as a centre of excellence for process scale-up and manufacturing services. The collaboration brings together Stelis’ end-to-end capabilities in high-yield bioprocess development from cell line to commercial manufacturing scale and MilliporeSigma’s industry leading technological expertise in bioprocessing.
The lab and a soon-to-be-completed cGMP manufacturing facility will house MilliporeSigma’s portfolio of Mobius® bioprocessing equipment and single-use manufacturing components. MilliporeSigma will provide process know-how and application knowledge to help establish the single-use platform technologies at Stelis as part of the collaboration.